Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Healius Limited ( (AU:HLS) ) has provided an update.
Healius Limited announced a change in the director’s interest, with Director John Mattick acquiring 200,000 ordinary shares through on-market trades. This acquisition reflects a significant increase in Mattick’s holdings, potentially indicating confidence in the company’s future performance and stability, which could positively influence stakeholder perceptions.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates within the healthcare industry, providing medical and diagnostic services. The company is known for its extensive network of pathology laboratories and diagnostic imaging centers, focusing on delivering accessible healthcare solutions across Australia.
Average Trading Volume: 6,548,766
Technical Sentiment Signal: Sell
Current Market Cap: A$624.5M
For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.